CONSORT diagram showing the flow of participants through each stage of the DOREPAR randomized trial for the main outcome (change of VAS). by Karel Joineau (21799908)

Subjects:

Design of the protocol. by Karel Joineau (21799908)

Subjects:

Effect of DE of <i>S. malaccense</i> and <i>S. samarangense</i> leaves on A) ATP, B) p-mTOR, C) beclin-1, and D) p-AMPK levels. by Fatma A. Moharram (9276104)

Effect of DE of <i>S. malaccense</i> and <i>S. samarangense</i> on A) GSH, B) SOD, C) TNF-α, D) IL-1β, E) p-NF-κB, and F) Caspase-3 levels. by Fatma A. Moharram (9276104)

Changes in RVVs during spontaneous circulation and during CPR. by Woo Jin Jung (3279570)

Comparison of histological lesion scores of lungs and brains from PRV-WT and PRV-UL4^mut infected mice. by Xiaohua Zhang (350570)

Subjects:

Comparison of histological lesion scores of lungs and brains from PRV-WT and PRV-UL4^mut infected piglets. by Xiaohua Zhang (350570)

Subjects:

The heart rate was similar among the groups. by Hongyu Li (1332669)

“…Following the overexpression of miRNA 221 in myocardium, there was a marked alleviation of myocardial injury and cardiomyocyte apoptosis and necrosis, significant enhancement of left ventricular systolic function, and marked decrease in the levels of PLB, p-PLB (Ser16), p-PLB (Thr17), caspase 3 and Cyt C, as well as a significant decrease in total calcium levels in myocardium.…”

S1 File - by Hongyu Li (1332669)

“…Following the overexpression of miRNA 221 in myocardium, there was a marked alleviation of myocardial injury and cardiomyocyte apoptosis and necrosis, significant enhancement of left ventricular systolic function, and marked decrease in the levels of PLB, p-PLB (Ser16), p-PLB (Thr17), caspase 3 and Cyt C, as well as a significant decrease in total calcium levels in myocardium.…”

Primer sequences for RT-qPCR. by Hongyu Li (1332669)

“…Following the overexpression of miRNA 221 in myocardium, there was a marked alleviation of myocardial injury and cardiomyocyte apoptosis and necrosis, significant enhancement of left ventricular systolic function, and marked decrease in the levels of PLB, p-PLB (Ser16), p-PLB (Thr17), caspase 3 and Cyt C, as well as a significant decrease in total calcium levels in myocardium.…”

Log2 fold change (FC), mean and standard deviation (SD) of each lipid specie from the normal liver (NL) and simple steatosis (SS) groups, and adjusted p-values. by Laia Bertran (3685147)

Graph of surface roughness values of specimens after testing with different particle sizes at a concentration of 4 mg/mL (a) Ra, Rq (b) Rz (c) Sa, Sq (d) Sz, Sp, Sv. by Yang Li (7082)

Root mean square deviation of wild-type AKR1C3 (green line) and mutant (H5Q) AKR1C3 (purple line) proteins. by Md. Akeruzzaman Shaon (21511929)

Boxplots display the median (as the central tendency) and the interquartile range (25th to 75th percentiles) as the bottom and top edges of the box. by Manal Ali Ahmad (16868808)

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”